Business

Pharmaniaga shares drop despite revenue spike

Q2 net profit climbs to RM13.7 mil from RM9.98 mil registered a year ago

Updated 4 years ago · Published on 23 Aug 2021 3:00PM

Pharmaniaga shares drop despite revenue spike
Pharmaniaga’s revenue soars 82% year-on-year to RM1.2 billion, mainly due to higher demand from all segments, including businesses in Indonesia. – Pharmaniaga Facebook pic, August 23, 2021

KUALA LUMPUR – Pharmaniaga’s shares were in the red in early trade today, despite posting a jump in revenue in the second quarter (Q2) of the financial year 2021.

At 10.20am, the counter eased one sen to 91.5 sen, with 6.31 million units traded.

On Friday, Pharmaniaga announced that its net profit for Q2, which ended on June 30, rose to RM13.7 million from RM9.98 million recorded a year ago.

Revenue soared 82% year-on-year (y-o-y) to RM1.2 billion, mainly due to higher demand from all segments, including businesses in Indonesia.

In its filing with Bursa Malaysia, the leading pharmaceuticals company said the significant increase in non-concession business was attributable to the sale of the Sinovac Covid-19 vaccine to the Health Ministry (MoH).

Moving forward, Pharmaniaga believes that it is well-positioned to leverage the robust opportunities that are offered by the growing healthcare sector.

In a research note, Malaysian Industrial Development Finance (MIDF) Research highlighted that in the first half of 2021, Pharmaniaga’s net profit rose by 13.8% y-o-y to RM36.8 million, which is above its expectation, while its revenue rose by 34.5% y-o-y to RM1.97 billion.

“Given Pharmaniaga’s capability to continuously manufacture fill-and-finish vaccines, it has the advantage and capacity to continuously supply vaccines to the federal and state governments, as well as the private sector, thus assuring that the national vaccination roll-out goes on smoothly and swiftly,” it said.

Hence, MIDF Research is maintaining its “buy” call on Pharmaniaga’s shares, with an unchanged target price (TP) of RM0.98.

Meanwhile, CGS-CIMB expects the company to see contribution from its Covid-19 vaccine sale ramp up in the second half of 2021 as a significant portion of the contracted 12 million doses earmarked for MoH was delivered in July, in line with the acceleration of the National Covid-19 Immunisation Programme.

“We keep our forecasts intact pending further details from its analyst briefing. We retain our ‘add’ call and TP of RM1.06,” it noted. – Bernama, August 23, 2021

Related News

Malaysia / 3w

Covid-19 cases in Malaysia stable, no deaths recorded this year – MOH

Malaysia / 1mth

Couple receive rude surprise when hospital hands them ‘wrong’ baby

Opinion / 1mth

'Brickfields didn’t fail. We failed it'

Trending / 2mth

Langkawi ferry to go out of business if trips are not reduced

Malaysia / 3mth

Bad move to channel EPF dividends into Account 3 for festive withdrawals, cautions economist

Malaysia / 6mth

Kuala Lumpur also hit by floods, nearly 14,000 victims nationwide

Spotlight

Malaysia

Grandfather charged with raping 12-year-old granddaughter

Malaysia

MACC application to stop Na'imah managing assets in Jersey to be heard on August 13

Malaysia

AI-powered probe uncovers SOCSO fraud syndicate exploiting disabled, identity thefts

Malaysia

Salesman pleads guilty to slashing motorcyclist, causing severe injuries

Malaysia

AirAsia warns job seekers of fake recruitment website stealing personal data, demanding fees

Malaysia

Malaysia Stadium Corporation CEO charged over alleged RM1m bribery solicitation

Malaysia

Johor MB to defend state seat in upcoming polls

By Alfian Z.M. Tahir

You may be interested

Business

US dollar weakens as markets await Warsh's first Fed decision

Business

Brent crude plummets below US$80 as US-Iran peace deal hopes eclipse Wall Street AI slump

Business

US dollar surges to three-month high as Fed signals possible rate hike

Business

KPJ posts strong FY2025 performance, sets sights on next growth phase

By Alfian Z.M. Tahir

Business

Oil prices slide as US-Iran peace deal raising hopes of supply recovery